CD30 CAR T-cells / New York Medical College - LARVOL DELTA

REACH-CD30: CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: New York Medical College

New P1 trial • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • TNFRSF8

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=21 | Not yet recruiting | Sponsor: New York Medical College | Trial completion date: Dec 2041 ➔ Dec 2040 | Initiation date: Jun 2025 ➔ Dec 2024 | Trial primary completion date: Dec 2040 ➔ Dec 2039

CAR T-Cell Therapy • Trial completion date • Trial initiation date • Trial primary completion date • Bone Marrow Transplantation • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation • TNFRSF8